Searching Polymorphic Markers Associated With The Genetic Predisposition To Develop Therapy-Related Myelodysplastic Syndromes And Acute Myelogenous Leukemia T-(Mds/Aml) After Myeloablative Chemotherapy.

INTRODUCTION: Therapy-related MDS/AML constitutes the most frequent secondary neoplasia and his incidence is increasing in the last years. This incidence is especially high when myeloablative chemotherapy is used before autologous stem cell transplantation (ASCT). Since for similar treatments only a percentage of the patients ends up by developing a secondary leukemia, it has been proposed the existence of some type of genetic predisposition associated to this syndrome.